To assess whether KRAS mutation status modifies the extent of differential gene expression between CRC and non-lesional tissue, we incorporated an interaction term—“tissue type (1 = CRC, 0 = normal) × KRAS mutation status (1 = mutant, 0 = wild-type)”—into the ANOVA model. Here, KRAS is linked to colorectal carcinoma.